Akari Therapeutics (NASDAQ:AKTX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note released on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Performance

Shares of NASDAQ AKTX opened at $1.19 on Wednesday. Akari Therapeutics has a 12 month low of $1.08 and a 12 month high of $5.50. The company has a 50-day simple moving average of $1.77 and a 200-day simple moving average of $2.59.

Institutional Investors Weigh In On Akari Therapeutics

An institutional investor recently raised its position in Akari Therapeutics stock. Omnia Family Wealth LLC increased its stake in Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 87,628 shares of the biopharmaceutical company’s stock after acquiring an additional 28,511 shares during the period. Omnia Family Wealth LLC owned approximately 1.55% of Akari Therapeutics worth $273,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 5.06% of the company’s stock.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.